Patents by Inventor Junji Kato

Junji Kato has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10355281
    Abstract: This invention relates to a conductive paste for lithium-ion battery positive electrodes and a mixture paste for a lithium ion battery positive electrode that have an easy-to-apply viscosity, even when a relatively small amount of a dispersion resin is incorporated. More specifically, the invention provides a conductive paste for lithium-ion battery positive electrodes, the conductive paste comprising a dispersion resin (A), conductive carbon (B), and a solvent (C), the dispersion resin (A) containing a resin (A1), the resin (A1) containing, as one constituent component, a polymerizable unsaturated group-containing monomer (A1-1) represented by a specific formula.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: July 16, 2019
    Assignees: KANSAI PAINT CO., LTD., TOYOTA JIDOSHA KABUSHIKI KAISHA
    Inventors: Junji Akahane, Koji Endo, Takanori Ito, Atsuya Kato, Hideki Hagiwara, Machiko Abe, Kosuke Iwase, You Kato, Kazuyuki Kuwano, Sachio Takeda
  • Publication number: 20190174445
    Abstract: To precisely synchronize system clocks, medium clocks, or the like of apparatuses with each other. A wireless apparatus includes a main control unit and a wireless control unit. Information regarding a correspondence between a clock that manages a time of the main control unit and a clock that manages a time of the wireless control unit is wirelessly sent to another wireless apparatus by the wireless control unit. This information regarding the correspondence includes information regarding a difference between the two clocks, information regarding a granularity ratio of the two clocks, and the like. For example, the wireless control unit sends the information regarding the correspondence as a part of a frame for measuring the time of the wireless control unit with respect to the other wireless apparatus or a part of a frame for connecting to the other wireless apparatus.
    Type: Application
    Filed: September 13, 2017
    Publication date: June 6, 2019
    Applicant: Sony Corporation
    Inventors: Takeshi ITAGAKI, Junji KATO, Hideyuki SUZUKI
  • Publication number: 20190090307
    Abstract: To prevent a decrease in transmission rate of an entirety of a system including devices that transmit data items with use of a plurality of channels ever, in a case where some of the channels change in condition, for example, decrease in transmission rate. In an information processing device including channel evaluation units, a channel selection unit, and a transmission control unit, the channel evaluation units evaluate, on the basis of an evaluation function, a plurality of channels that transmit data items via wireless communication. The channel selection unit performs selection from the plurality of channels on the basis of results of the evaluations. The transmission control unit transmits the data items to the plurality of channels subjected to the selection.
    Type: Application
    Filed: January 26, 2017
    Publication date: March 21, 2019
    Applicant: SONY CORPORATION
    Inventors: KAZUNORI HAYASHI, JUNJI KATO, TOMOAKI MATSUMURA, OSAMU YOSHIMURA, KENSAKU WAKUDA, TOMOYA OIKAWA
  • Patent number: 9757462
    Abstract: The invention relates to a combined pharmaceutical composition or pharmaceutical preparation, comprising a first component containing a first ligand for a polyspecific lectin in a reticuloendothelial cell and a second component containing a carrier, a labeling agent, or a medicament for treating a disease associated with a target cell, each of which is targeted by a second ligand for a polyspecific lectin in a reticuloendothelial cell different from the first ligand, and also relates to a method for labeling a target cell and a method for treating a disease associated with a target cell, each using the same.
    Type: Grant
    Filed: October 20, 2011
    Date of Patent: September 12, 2017
    Assignee: Sapporo Medical University
    Inventors: Junji Kato, Rishu Takimoto
  • Patent number: 9577164
    Abstract: A semiconductor light emitting device, which can endure a dicing step for singulation, is superior in resistance to a high/low thermal cycle, and exhibits a high light extraction efficiency, and an optical film, which can be used favorably for producing the semiconductor light emitting device, are to be provided.
    Type: Grant
    Filed: September 1, 2014
    Date of Patent: February 21, 2017
    Assignee: ASAHI KASEI E-MATERIALS CORPORATION
    Inventors: Hiroyuki Tsujimoto, Atsushi Suzuki, Junji Kato, Shozo Takada
  • Publication number: 20160211425
    Abstract: A semiconductor light emitting device, which can endure a dicing step for singulation, is superior in resistance to a high/low thermal cycle, and exhibits a high light extraction efficiency, and an optical film, which can be used favorably for producing the semiconductor light emitting device, are to be provided.
    Type: Application
    Filed: September 1, 2014
    Publication date: July 21, 2016
    Applicant: Asahi Kasei E-materials Corporation
    Inventors: Hiroyuki TSUJIMOTO, Atsushi SUZUKI, Junji KATO, Shozo TAKADA
  • Publication number: 20160038593
    Abstract: An astrocyte-specific drug carrier containing a retinoid derivative and/or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative such as vitamin A or a vitamin A analog or encapsulating the same in the drug carrier, a drug for therapeutic use can be delivered specifically to astrocytes. As a result, an astrocyte-related disease can be efficiently and effectively inhibited or prevented while minimizing side effects. As the drug inhibiting the activity or growth of astrocytes, for example, a siRNA against HSP47 which is a collagen-specific molecule chaperone may be encapsulated in the drug carrier. Thus, the secretion of type I to type IV collagens can be inhibited at the same time and, in its turn, fibrosis can be effectively inhibited.
    Type: Application
    Filed: October 21, 2015
    Publication date: February 11, 2016
    Inventors: Yoshiro Niitsu, Junji Kato, Yasushi Sato
  • Publication number: 20160038597
    Abstract: The present invention relates to a carrier that is targeted at fucosylated molecule-producing cells, which comprises an effective amount of fucose for targeting said cells, to a composition comprising the carrier, and to a method for treating and diagnosing a disease related to fucosylated molecule-producing cells utilizing said carrier, etc. The carrier of the present invention enables to deliver a substance specifically to fucosylated molecule-producing cells.
    Type: Application
    Filed: October 20, 2011
    Publication date: February 11, 2016
    Inventors: Junji Kato, Rishu Takimoto
  • Publication number: 20150017098
    Abstract: The present invention relates to a carrier that is targeted at fucosylated molecule-producing cells, which comprises an effective amount of fucose for targeting said cells, to a composition comprising the carrier, and to a method for treating and diagnosing a disease related to fucosylated molecule-producing cells utilizing said carrier, etc. The carrier of the present invention enables to deliver a substance specifically to fucosylated molecule-producing cells.
    Type: Application
    Filed: October 20, 2011
    Publication date: January 15, 2015
    Inventors: Junji Kato, Rishu Takimoto
  • Patent number: 8761982
    Abstract: A vehicle includes a first drive device and a second drive device. The first drive device includes a motor, a motor control device, a connection-disconnection device, and a connection-disconnection device controller. When the vehicle is driven in a state where a driving force of the first drive device is substantially zero, or the vehicle is driven only by a driving force of the second drive device, the connection-disconnection device controller couples the connection-disconnection device to establish a connected state of the connection-disconnection device. The motor control device is configured to perform loss reduction control on the motor to reduce at least one of a loss of the motor and a loss in a power transmission path in power transmitted to the first driving wheel, by establishing the connected state of the connection-disconnection device.
    Type: Grant
    Filed: April 5, 2012
    Date of Patent: June 24, 2014
    Assignee: Honda Motor Co., Ltd.
    Inventors: Akihiro Yamamoto, Junji Kato, Yuichi Nakamura, Hiroshi Murakami
  • Patent number: 8652526
    Abstract: An astrocyte-specific drug carrier containing a retinoid derivative and/or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative such as vitamin A or a vitamin A analog or encapsulating the same in the drug carrier, a drug for therapeutic use can be delivered specifically to astrocytes. As a result, an astrocyte-related disease can be efficiently and effectively inhibited or prevented while minimizing side effects. As the drug inhibiting the activity or growth of astrocytes, for example, a siRNA against HSP47 which is a collagen-specific molecule chaperone may be encapsulated in the drug carrier. Thus, the secretion of type I to type IV collagens can be inhibited at the same time and, in its turn, fibrosis can be effectively inhibited.
    Type: Grant
    Filed: April 4, 2012
    Date of Patent: February 18, 2014
    Assignee: Nitto Denko Corporation
    Inventors: Yoshiro Niitsu, Junji Kato, Yasushi Sato
  • Publication number: 20140030186
    Abstract: The invention relates to a combined pharmaceutical composition or pharmaceutical preparation, comprising a first component containing a first ligand for a polyspecific lectin in a reticuloendothelial cell and a second component containing a carrier, a labeling agent, or a medicament for treating a disease associated with a target cell, each of which is targeted by a second ligand for a polyspecific lectin in a reticuloendothelial cell different from the first ligand, and also relates to a method for labeling a target cell and a method for treating a disease associated with a target cell, each using the same.
    Type: Application
    Filed: October 20, 2011
    Publication date: January 30, 2014
    Inventors: Junji Kato, Rishu Takimoto
  • Patent number: 8591953
    Abstract: An astrocyte-specific drug carrier containing a retinoid derivative and/or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative such as vitamin A or a vitamin A analog or encapsulating the same in the drug carrier, a drug for therapeutic use can be delivered specifically to astrocytes. As a result, an astrocyte-related disease can be efficiently and effectively inhibited or prevented while minimizing side effects. As the drug inhibiting the activity or growth of astrocytes, for example, a siRNA against HSP47 which is a collagen-specific molecule chaperone may be encapsulated in the drug carrier. Thus, the secretion of type I to type IV collagens can be inhibited at the same time and, in its turn, fibrosis can be effectively inhibited.
    Type: Grant
    Filed: April 4, 2012
    Date of Patent: November 26, 2013
    Assignee: Nitto Denko Corporation
    Inventors: Yoshiro Niitsu, Junji Kato, Yasushi Sato
  • Patent number: 8410745
    Abstract: When a short-circuit failure of any of switch portions (13) including switch elements (11) and parallel-connected feedback diodes (12) of an inverter circuit (7) is detected during the operation of a motor (1), a switch portion (13) where the short-circuit failure has occurred is checked for whether it is on the positive polarity side or the negative polarity side. The switch elements (11) are so controlled that all the switch portions (13) on the same polarity side as where the short-circuit has occurred are brought into a conducted state and all the others are disconnected. This prevents a large electric current from flowing into each switch portion of the inverter circuit without requiring any switch to block the power distribution between a motor and the inverter circuit when a short-circuit failure of the switch portion of the inverter circuit occurs.
    Type: Grant
    Filed: February 18, 2008
    Date of Patent: April 2, 2013
    Assignee: Honda Motor Co., Ltd.
    Inventors: Masaharu Hosoda, Yuji Saito, Yasuyuki Danjo, Hideki Inoue, Tetsu Sugiyama, Junji Kato
  • Publication number: 20130011464
    Abstract: An astrocyte-specific drug carrier containing a retinoid derivative and/or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative such as vitamin A or a vitamin A analog or encapsulating the same in the drug carrier, a drug for therapeutic use can be delivered specifically to astrocytes. As a result, an astrocyte-related disease can be efficiently and effectively inhibited or prevented while minimizing side effects. As the drug inhibiting the activity or growth of astrocytes, for example, a siRNA against HSP47 which is a collagen-specific molecule chaperone may be encapsulated in the drug carrier. Thus, the secretion of type I to type IV collagens can be inhibited at the same time and, in its turn, fibrosis can be effectively inhibited.
    Type: Application
    Filed: April 4, 2012
    Publication date: January 10, 2013
    Applicant: Nitto Denko Corporation
    Inventors: Yoshiro Niitsu, Junji Kato, Yasushi Sato
  • Publication number: 20120259492
    Abstract: A vehicle includes a first drive device and a second drive device. The first drive device includes a motor, a motor control device, a connection-disconnection device, and a connection-disconnection device controller. When the vehicle is driven in a state where a driving force of the first drive device is substantially zero, or the vehicle is driven only by a driving force of the second drive device, the connection-disconnection device controller couples the connection-disconnection device to establish a connected state of the connection-disconnection device. The motor control device is configured to perform loss reduction control on the motor to reduce at least one of a loss of the motor and a loss in a power transmission path in power transmitted to the first driving wheel, by establishing the connected state of the connection-disconnection device.
    Type: Application
    Filed: April 5, 2012
    Publication date: October 11, 2012
    Applicant: Honda Motor Co., Ltd
    Inventors: Akihiro YAMAMOTO, Junji Kato, Yuichi Nakamura, Hiroshi Murakami
  • Publication number: 20120189691
    Abstract: An astrocyte-specific drug carrier containing a retinoid derivative and/or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative such as vitamin A or a vitamin A analog or encapsulating the same in the drug carrier, a drug for therapeutic use can be delivered specifically to astrocytes. As a result, an astrocyte-related disease can be efficiently and effectively inhibited or prevented while minimizing side effects. As the drug inhibiting the activity or growth of astrocytes, for example, a siRNA against HSP47 which is a collagen-specific molecule chaperone may be encapsulated in the drug carrier. Thus, the secretion of type I to type IV collagens can be inhibited at the same time and, in its turn, fibrosis can be effectively inhibited.
    Type: Application
    Filed: April 4, 2012
    Publication date: July 26, 2012
    Applicant: NITTO DENKO CORPORATION
    Inventors: YOSHIRO NIITSU, JUNJI KATO, YASUSHI SATO
  • Patent number: 8178124
    Abstract: An astrocyte-specific drug carrier containing a retinoid derivative and/or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative such as vitamin A or a vitamin A analog or encapsulating the same in the drug carrier, a drug for therapeutic use can be delivered specifically to astrocytes. As a result, an astrocyte-related disease can be efficiently and effectively inhibited or prevented while minimizing side effects. As the drug inhibiting the activity or growth of astrocytes, for example, a siRNA against HSP47 which is a collagen-specific molecule chaperone may be encapsulated in the drug carrier. Thus, the secretion of type I to type IV collagens can be inhibited at the same time and, in its turn, fibrosis can be effectively inhibited.
    Type: Grant
    Filed: September 29, 2011
    Date of Patent: May 15, 2012
    Assignee: Nitto Denko Corporation
    Inventors: Yoshiro Niitsu, Junji Kato, Yasushi Sato
  • Patent number: 8173170
    Abstract: An astrocyte-specific drug carrier containing a retinoid derivative and/or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative such as vitamin A or a vitamin A analog or encapsulating the same in the drug carrier, a drug for therapeutic use can be delivered specifically to astrocytes. As a result, an astrocyte-related disease can be efficiently and effectively inhibited or prevented while minimizing side effects. As the drug inhibiting the activity or growth of astrocytes, for example, a siRNA against HSP47 which is a collagen-specific molecule chaperone may be encapsulated in the drug carrier. Thus, the secretion of type I to type IV collagens can be inhibited at the same time and, in its turn, fibrosis can be effectively inhibited.
    Type: Grant
    Filed: December 22, 2005
    Date of Patent: May 8, 2012
    Assignee: Nitto Denko Corporation
    Inventors: Yoshiro Niitsu, Junji Kato, Yasushi Sato
  • Publication number: 20120076852
    Abstract: An astrocyte-specific drug carrier containing a retinoid derivative and/or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative such as vitamin A or a vitamin A analog or encapsulating the same in the drug carrier, a drug for therapeutic use can be delivered specifically to astrocytes. As a result, an astrocyte-related disease can be efficiently and effectively inhibited or prevented while minimizing side effects. As the drug inhibiting the activity or growth of astrocytes, for example, a siRNA against HSP47 which is a collagen-specific molecule chaperone may be encapsulated in the drug carrier. Thus, the secretion of type I to type IV collagens can be inhibited at the same time and, in its turn, fibrosis can be effectively inhibited.
    Type: Application
    Filed: September 29, 2011
    Publication date: March 29, 2012
    Applicant: Nitto Denko Corporation
    Inventors: Yoshiro Niitsu, Junji Kato, Yasushi Sato